NKure Therapeutics Advances CAR T Therapy in India with CRISPR Collaboration

Deal News | May 08, 2025 | Endiya Partners Ltd

NKure Therapeutics has announced a strategic partnership with CRISPR Therapeutics to co-develop CTX112™, a CRISPR-engineered cell therapy product aimed at treating B-cell lymphomas in India. This collaboration seeks to leverage advanced gene-editing technologies to offer an off-the-shelf product that could significantly reduce manufacturing times and treatment delays, addressing a critical need in the Indian healthcare sector. Endiya Partners Ltd., a notable private equity firm, is backing NKure Therapeutics in this endeavor. The initiative highlights the increasing focus on innovative biotech solutions to combat the rising incidence of B-cell lymphomas in India, providing a scalable and efficient alternative to current therapies.

Sectors

Biotechnology
Healthcare
Private Equity

Geography

India – The strategic collaboration and development of CAR T therapy are focused on addressing healthcare needs specific to the Indian market.

Industry

Biotechnology – This industry is relevant due to the development of CRISPR-engineered therapies and the focus on advanced biotechnological solutions to treat diseases like B-cell lymphomas.
Healthcare – The healthcare industry is central to the article, as the collaboration aims to provide innovative treatments for B-cell lymphomas in India.
Private Equity – Private equity plays a role as Endiya Partners is backing the development and strategic partnership for the new therapy.

Financials

Participants

Name	Role	Type	Description
NKure Therapeutics	Target Company	Company	A biotechnology company working on developing innovative therapies for cancer treatment.
CRISPR Therapeutics	Partner Company	Company	A leading gene-editing company collaborating with NKure on the CTX112™ project.
Endiya Partners Ltd.	Private Equity Firm	Company	A private equity firm supporting NKure Therapeutics in this strategic health initiative.